EVL Stock Overview
A performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Evolus, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.30 |
| 52 Week High | US$15.90 |
| 52 Week Low | US$8.50 |
| Beta | 1.31 |
| 11 Month Change | -16.33% |
| 3 Month Change | -10.87% |
| 1 Year Change | 44.71% |
| 33 Year Change | 134.29% |
| 5 Year Change | -3.91% |
| Change since IPO | 33.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| EVL | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 10.8% | -1.2% | -0.02% |
| 1Y | 44.7% | -20.1% | 8.2% |
Return vs Industry: EVL exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: EVL exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| EVL volatility | |
|---|---|
| EVL Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EVL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: EVL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 322 | David Moatazedi | www.evolus.com |
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names.
Evolus, Inc. Fundamentals Summary
| EVL fundamental statistics | |
|---|---|
| Market cap | €792.93m |
| Earnings (TTM) | -€53.26m |
| Revenue (TTM) | €238.47m |
3.2x
P/S Ratio-14.4x
P/E RatioIs EVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVL income statement (TTM) | |
|---|---|
| Revenue | US$248.33m |
| Cost of Revenue | US$74.64m |
| Gross Profit | US$173.69m |
| Other Expenses | US$229.15m |
| Earnings | -US$55.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.88 |
| Gross Margin | 69.94% |
| Net Profit Margin | -22.33% |
| Debt/Equity Ratio | 2,057.9% |
How did EVL perform over the long term?
See historical performance and comparison